Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

The usual approach for most patients who are not in a study is treatment with docetaxel. This study is being done to answer the following question: Can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual approach? This study is being done to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach is defined as the care most people get for prostate cancer.

Trial Details

NCT ID
NCT06439225
Phase
PHASE3
Sponsor
Canadian Cancer Trials Group
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Docetaxel
  • Carboplatin
Locations (sample)
  • Calgary, Alberta, Canada|51.05011,-114.08529
  • Edmonton, Alberta, Canada|53.55014,-113.46871
  • Vancouver, British Columbia, Canada|49.24966,-123.11934
  • Brampton, Ontario, Canada|43.68341,-79.76633
  • Kitchener, Ontario, Canada|43.42537,-80.5112

Key Eligibility Criteria

  • Histologic diagnosis of adenocarcinoma of the prostate. The presence of neuroendocrine or small cell carcinoma will be exclusionary
  • Prior treatment with any ARPI, such as abiraterone, enzalutamide, apalutamide, or darotlutamide, is required.
  • Participants must have recovered to ≤ grade 1 from all reversible toxicity related to prior systemic or radiation therapy, with the exception of ch…
  • Longest of one of the following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →